PGLYRP4/PGRP-I beta Antibody (186C426)

Western Blot: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721]

Western Blot: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721] - Analysis in cell lysates from human brain using a dilution of 2 ug/ml.

Immunocytochemistry/ Immunofluorescence: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721]

PGLYRP4-PGRP-I-beta-Antibody-186C426-Immunocytochemistry-Immunofluorescence-NB100-56721-img0006.jpg

Immunohistochemistry: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721] -

Immunohistochemistry: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721] - NF-kappa B p65 activation was induced by HKCA & inhibited by dectin-1 neutralizing antibody & NF-kappa B activation inhibitor quinazoline (NF-kappa B-I) in HCECs.A. HCECs were exposed to HKCA (106 cells/ml) with prior incubation in the absence or presence of isotype IgG (10μg/ml), dectin-1 neutralizing Ab (10μg/ml), BAY11-7082 (10μM) or NF-kappa B activation inhibitor quinazoline (NF-kappa B-I, 10μM) for 1 h. HCECs were treated with 106 cells/ml HKCA for 48 hours in 8-chamber slides & examined by immunofluorescent staining for PGLYRPs 2–4. B. HCECs were treated for 4 hours in 8-chamber slides & were fixed in acetone for immunofluroscent staining total p65 (nuclear translocation) (green). C. The percentages of positive cells of PGLYRPs 2–4 staining in HCECs in A was quantified. D. The percentages of NF-ĸB p65 nuclear staining positive cells in B was quantified. Images are representatives from three independent experiments. Results shown are the mean ± SD of four independent experiments; *** p<0.001, as compared with normal control; ^^ p<0.005, ^^^ p<0.001, as compared with HCECs exposed to HKCA. Magnification: 400Х (bar = 25μm). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26039076), licensed under a CC-BY license. Not internally tested by Novus Biologicals.